Michael Geffner Net Worth

The estimated Net Worth of Michael Geffner is at least $4.59 Million dollars as of 24 July 2024. Michael Geffner owns over 3,456 units of Immunovant Inc stock worth over $4,013,548 and over the last few years Michael sold IMVT stock worth over $573,211.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Michael Geffner IMVT stock SEC Form 4 insiders trading

Michael has made over 3 trades of the Immunovant Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Michael sold 3,456 units of IMVT stock worth $95,939 on 24 July 2024.

The largest trade Michael's ever made was selling 10,101 units of Immunovant Inc stock on 26 January 2024 worth over $383,030. On average, Michael trades about 4,205 units every 45 days since 2024. As of 24 July 2024 Michael still owns at least 138,160 units of Immunovant Inc stock.

You can see the complete history of Michael Geffner stock trades at the bottom of the page.

What's Michael Geffner's mailing address?

Michael's mailing address filed with the SEC is C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK, NY, 10018.

Insiders trading at Immunovant Inc

Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann, and Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.

What does Immunovant Inc do?

immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.

Complete history of Michael Geffner stock trades at Immunovant Inc

Immunovant Inc executives and stock owners

Immunovant Inc executives and other stock owners filed with the SEC include:

• Peter Salzmann,
  Chief Executive Officer, Director
• Pamela Connealy,
  Chief Financial Officer
• Dr. Peter Salzmann M.B.A., M.D.,
  CEO & Director
• Frank Torti,
  Chairman of the Board
• Dr. Julia G. Butchko Ph.D.,
  Chief Devel. & Technology Officer
• Andrew Fromkin,
  Independent Director
• Douglas Hughes,
  Independent Director
• Atul Pande,
  Independent Director
• Dr. Frank M. Torti M.B.A., M.D., MBA,
  Exec. Chairperson of the Board
• George Migausky,
  Independent Director
• Eric Venker,
  Director
• W. Bradford Middlekauff,
  General Counsel
• Michael Elliott,
  Chief Scientific Officer
• Julia Butchko,
  Chief Development and Technology Officer
• Dr. William L. Macias M.D., Ph.D.,
  Chief Medical Officer
• Lauren Schrier M.B.A.,
  VP of Marketing
• Mark S. Levine,
  Chief Legal Officer & Corp. Sec.
• Tom Dorney M.B.A., M.S.,
  Director of Investor Relations & Strategy
• Eva Renee Barnett M.B.A.,
  Chief Financial Officer
• Sciences Holdings, Llc Health,
  10% owner
• Robert K Zeldin,
  Chief Medical Officer
• Myrtle S Potter,
  Director
• Jay S Stout,
  Chief Technology Officer
• Rita Jain,
  Chief Medical Officer
• William L. Macias,
  Chief Medical Officer
• Eva Renee Barnett,
  Chief Financial Officer
• Mark S. Levine,
  Chief Legal Officer
• Sciences Ltd. Roivant,
  
• Michael Geffner,
  Chief Medical Officer